Interventional Endoscopic Ultrasound (EUS) (on demand)-EUS Ablation

Video Transcription

Video Summary

Dr. Jad Abimansour and a panel discuss endoscopic ultrasound (EUS)-guided ablation of pancreatic lesions. They review referrals including functional and nonfunctional neuroendocrine tumors, pancreatic cysts, and selected unresectable or metastatic tumors. Treatment options include ethanol, radiofrequency ablation (RFA), irreversible electroporation, and microwave ablation; RFA is generally favored for cystic lesions when fluid can be aspirated, while chemoablation may carry greater pancreatitis risk.<br /><br />Patient selection requires multidisciplinary review and careful assessment of nearby structures, particularly the pancreatic duct. Lesions within about 1–2 mm of the duct raise pancreatitis risk, and prophylactic duct stenting may be considered. During RFA, operators monitor tissue changes and rising impedance, while recognizing that early imaging can be misleading. Follow-up imaging is generally delayed, ideally around three months, and some patients need repeat treatment.<br /><br />For beginners, a roughly 1 cm insulinoma in the body or tail, away from the duct, is an ideal starting case because ablation can rapidly relieve hypoglycemia.

Meta Tag

Concept Endoscopic Ultrasound-Guided Pancreatic Ablation

Concept Pancreatic Neuroendocrine Tumor

Concept Pancreatic Metastasis

Concept Radiofrequency Ablation

Concept Functional Neuroendocrine Tumor

Keywords

endoscopic ultrasound

pancreatic lesions

radiofrequency ablation

neuroendocrine tumors

pancreatic cysts

pancreatic duct

pancreatic lesion ablation

pancreatic neuroendocrine tumors

pancreatic duct risk